Celgene, Acceleron Pharma Report Prelim. Data from Ongoing Phase 2 Trials in Patients with Lower Risk MDS:: Luspatercept, Sotatercept Increased Hemoglobin Levels

By: via Benzinga
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced preliminary data from ongoing phase 2 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.